Genes may determine which smoking cessation treatment works best

Kicking the habit may soon become easier for the nation’s 45 million smokers. For the first time, researchers have identified patterns of genes that appear to influence how well individuals respond to specific smoking cessation treatments.

Scientists at Duke University Medical Center, the National Institute of Drug Abuse, University of Pennsylvania and Brown University scanned the entire human genome in a comprehensive search for genes that could determine treatment outcome. They identified several genetic variations that seem to indicate the likelihood of success or failure of nicotine replacement therapy (NRT) and bupropion (Zyban).

Their findings appear in the June issue of Archives of General Psychiatry.

“This takes us a big step forward in being able to tailor treatment to individual smokers to provide the therapies that are most likely to benefit them,” explains Jed Rose, Ph.D., director of Duke’s Center for Nicotine and Smoking Cessation Research and one of the study’s authors. “In a few years, a simple blood test may provide physicians with enough information to recommend one treatment over another.”

In previous studies, the researchers performed the first genome-wide scan of more than 520,000 genetic markers taken from blood samples of smokers entered in a quit-smoking trial. When they compared the genes of smokers who had successfully kicked the habit to those who failed to quit, they found clusters of positive results in gene variants present more frequently in the successful quitters. The current findings “confirmed that most of the genetic markers we previously identified remain significant predictors of who will have the most likelihood of success,” says Rose.

George Uhl, MD, PhD, chief of the molecular neurobiology research branch at the National Institute on Drug Abuse and lead author of the study, says their work marks significant inroads in the study of smoking cessation. “It helps us understand why some people are able to quit smoking more easily than others.”

The latest findings, he added, “provide potential clues to match individuals with treatments”

Both NRT and Zyban have proven effective at helping people abstain from smoking, but use different pharmacological mechanisms to achieve that abstinence.

In the current study, Dr Uhl’s laboratory analyzed the DNA of 550 smokers entered into quit-smoking studies in which they were randomly assigned to either placebo, NRT or bupropion. The studies took place at Duke, University of Pennsylvania or Brown University. They assessed quit-smoking success several weeks later and found 41 gene variants specific to smokers who successfully stopped smoking using NRT, and 26 bupropion-specific genes. “Everybody has some version of these genes, but different people have distinct variants," Rose said.

The researchers stress that the presence of these genetic variants alone is not enough to completely predict specific treatment success or failure. Rose also cautioned that not enough is known, yet, about what role the genes play. ”It may be that each gene is adding its own influence. We still don’t know if each gene interacts with each other or if each gene is casting its vote and we’re simply counting up all the votes.”

In their next phase of research, currently ongoing, the researchers are working on confirming these initial findings. In the near future, they plan to expand their studies to include varenicline (Chantix) and other smoking cessation treatments. “We also plan to look at genetic predictors of behavioral therapies to see who they will work best in,” Rose said.

Source: Duke University

Related stories:

If your first cigarette gave you a buzz and you now smoke, a gene may be to blame
Anyone who has ever tried smoking probably remembers that first cigarette vividly. For some, it brought a wave of nausea or a nasty coughing fit. For others, those first puffs also came with a rush of pleasure or "buzz."
Genetic variations put youth at higher risk for lifetime of tobacco addiction
Common genetic variations affecting nicotine receptors in the nervous system can significantly increase the chance that European Americans who begin smoking by age 17 will struggle with lifelong nicotine addiction, according to researchers at the University of Utah and their colleagues at University of Wisconsin-Madison. The study, published in the July 11, 2008 issue of PLoS Genetics, highlights the importance of public health efforts to reduce the number of youth who begin smoking.
Faulty DNA repair could be a risk factor for lung cancer in nonsmokers
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.
Researchers find common gene disorder doubles risk of lung cancer, even among nonsmokers
Mayo Clinic researchers have found that carrying a common genetic disorder doubles the risk of developing lung cancer in smokers and nonsmokers. The study is published in the May 26 issue of the Archives of Internal Medicine, a journal published by the American Medical Association.
Study finds smoking related to subset of colorectal cancers
Smoking puts older women at significant risk for loss of DNA repair proteins that are critical for defending against development of some colorectal cancers, according to research from a team led by Mayo Clinic scientists.
Mouth may tell the tale of lung damage caused by smoking
Cells lining the mouth reflect the molecular damage that smoking does to the lining of the lungs, researchers at The University of Texas M. D. Anderson Cancer Center report today at the annual meeting of the American Association for Cancer Research.
Researchers ID gene linked to lung cancer
Researchers at Johns Hopkins, as part of a large, multi-institutional study, have found one gene variant that is linked to an increased risk of lung cancer. The study will be published in the April 3 issue of Nature Genetics.
Genetic variations raise lung cancer risk for smokers and ex-smokers
Two common inherited genetic variations are associated with increased risk of lung cancer for smokers and former smokers, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 2 in the online edition of Nature Genetics.

News discussion:

Medicine & Health news